Lixisenatide (Lyxumia®) is recommended as an option for restricted use within NHS Wales. Lixisenatide (Lyxumia®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control:

• In combination with basal insulin, with or without oral glucose-lowering medicinal products, in patients uncontrolled on basal insulin;
• In combination with oral glucose-lowering medicinal products in patients uncontrolled on two or more oral glucose-lowering medicinal products.

Lixisenatide (Lyxumia®) is not recommended for use within NHS Wales outside of these circumstances.